Benitec Biopharma (BNTC) Competitors

$12.50 +0.13 (+1.05%)

As of 02:02 PM Eastern

BNTC vs. GLUE, ZYME, SNDX, ANAB, and ABCL

Should you buy Benitec Biopharma stock or one of its competitors? MarketBeat compares Benitec Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Benitec Biopharma include Monte Rosa Therapeutics (GLUE), Zymeworks (ZYME), Syndax Pharmaceuticals (SNDX), AnaptysBio (ANAB), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical products" industry.

How does Benitec Biopharma compare to Monte Rosa Therapeutics?

Monte Rosa Therapeutics (NASDAQ:GLUE) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are held by institutional investors. 6.4% of Monte Rosa Therapeutics shares are held by insiders. Comparatively, 4.8% of Benitec Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Benitec Biopharma has lower revenue, but higher earnings than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Benitec Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$123.67M	15.70	-$38.63M	-$1.48	N/A
Benitec Biopharma	N/A	N/A	-$37.92M	-$1.14	N/A

Benitec Biopharma has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -302.69%. Benitec Biopharma's return on equity of -34.82% beat Monte Rosa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-302.69%	-40.99%	-25.94%
Benitec Biopharma	N/A	-34.82%	-34.11%

In the previous week, Monte Rosa Therapeutics had 9 more articles in the media than Benitec Biopharma. MarketBeat recorded 10 mentions for Monte Rosa Therapeutics and 1 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 1.87 beat Monte Rosa Therapeutics' score of -0.06 indicating that Benitec Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Monte Rosa Therapeutics	Neutral
Benitec Biopharma	Very Positive

Monte Rosa Therapeutics presently has a consensus price target of $32.50, suggesting a potential upside of 41.37%. Benitec Biopharma has a consensus price target of $27.00, suggesting a potential upside of 116.88%. Given Benitec Biopharma's higher possible upside, analysts plainly believe Benitec Biopharma is more favorable than Monte Rosa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Monte Rosa Therapeutics has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market. Comparatively, Benitec Biopharma has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market.

Summary

Monte Rosa Therapeutics beats Benitec Biopharma on 8 of the 15 factors compared between the two stocks.

How does Benitec Biopharma compare to Zymeworks?

Zymeworks (NASDAQ:ZYME) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

Zymeworks has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market. Comparatively, Benitec Biopharma has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market.

In the previous week, Zymeworks had 8 more articles in the media than Benitec Biopharma. MarketBeat recorded 9 mentions for Zymeworks and 1 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 1.87 beat Zymeworks' score of 0.94 indicating that Benitec Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Zymeworks	Positive
Benitec Biopharma	Very Positive

Benitec Biopharma has a net margin of 0.00% compared to Zymeworks' net margin of -126.92%. Benitec Biopharma's return on equity of -34.82% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-126.92%	-37.97%	-25.31%
Benitec Biopharma	N/A	-34.82%	-34.11%

Benitec Biopharma has lower revenue, but higher earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Benitec Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$81.26M	21.48	-$81.13M	-$1.37	N/A
Benitec Biopharma	N/A	N/A	-$37.92M	-$1.14	N/A

Zymeworks presently has a consensus price target of $36.67, suggesting a potential upside of 53.36%. Benitec Biopharma has a consensus price target of $27.00, suggesting a potential upside of 116.88%. Given Benitec Biopharma's higher possible upside, analysts plainly believe Benitec Biopharma is more favorable than Zymeworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

92.9% of Zymeworks shares are owned by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are owned by institutional investors. 33.5% of Zymeworks shares are owned by company insiders. Comparatively, 4.8% of Benitec Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Zymeworks beats Benitec Biopharma on 9 of the 16 factors compared between the two stocks.

How does Benitec Biopharma compare to Syndax Pharmaceuticals?

Benitec Biopharma (NASDAQ:BNTC) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Benitec Biopharma has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market. Comparatively, Syndax Pharmaceuticals has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

52.2% of Benitec Biopharma shares are held by institutional investors. 4.8% of Benitec Biopharma shares are held by insiders. Comparatively, 4.8% of Syndax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Benitec Biopharma presently has a consensus target price of $27.00, indicating a potential upside of 116.88%. Syndax Pharmaceuticals has a consensus target price of $42.55, indicating a potential upside of 93.48%. Given Benitec Biopharma's higher probable upside, equities analysts clearly believe Benitec Biopharma is more favorable than Syndax Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

In the previous week, Syndax Pharmaceuticals had 1 more articles in the media than Benitec Biopharma. MarketBeat recorded 2 mentions for Syndax Pharmaceuticals and 1 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 1.87 beat Syndax Pharmaceuticals' score of 1.43 indicating that Benitec Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Benitec Biopharma	Very Positive
Syndax Pharmaceuticals	Positive

Benitec Biopharma has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -111.88%. Benitec Biopharma's return on equity of -34.82% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Benitec Biopharma	N/A	-34.82%	-34.11%
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%

Benitec Biopharma has higher earnings, but lower revenue than Syndax Pharmaceuticals. Benitec Biopharma is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Benitec Biopharma	N/A	N/A	-$37.92M	-$1.14	N/A
Syndax Pharmaceuticals	$217.17M	8.97	-$285.42M	-$2.79	N/A

Summary

Benitec Biopharma beats Syndax Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Benitec Biopharma compare to AnaptysBio?

AnaptysBio (NASDAQ:ANAB) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

Benitec Biopharma has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. Benitec Biopharma's return on equity of -34.82% beat AnaptysBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AnaptysBio	-11.53%	-1,101.24%	-7.75%
Benitec Biopharma	N/A	-34.82%	-34.11%

52.2% of Benitec Biopharma shares are held by institutional investors. 33.5% of AnaptysBio shares are held by company insiders. Comparatively, 4.8% of Benitec Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

AnaptysBio has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market. Comparatively, Benitec Biopharma has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market.

AnaptysBio presently has a consensus price target of $81.82, suggesting a potential upside of 27.59%. Benitec Biopharma has a consensus price target of $27.00, suggesting a potential upside of 116.88%. Given Benitec Biopharma's higher probable upside, analysts clearly believe Benitec Biopharma is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

AnaptysBio has higher revenue and earnings than Benitec Biopharma. AnaptysBio is trading at a lower price-to-earnings ratio than Benitec Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$232.39M	8.03	-$13.23M	-$1.08	N/A
Benitec Biopharma	N/A	N/A	-$37.92M	-$1.14	N/A

In the previous week, AnaptysBio and AnaptysBio both had 1 articles in the media. AnaptysBio's average media sentiment score of 1.89 beat Benitec Biopharma's score of 1.87 indicating that AnaptysBio is being referred to more favorably in the media.

Company	Overall Sentiment
AnaptysBio	Very Positive
Benitec Biopharma	Very Positive

Summary

AnaptysBio beats Benitec Biopharma on 9 of the 14 factors compared between the two stocks.

How does Benitec Biopharma compare to AbCellera Biologics?

AbCellera Biologics (NASDAQ:ABCL) and Benitec Biopharma (NASDAQ:BNTC) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Benitec Biopharma has lower revenue, but higher earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Benitec Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	33.07	-$146.41M	-$0.48	N/A
Benitec Biopharma	N/A	N/A	-$37.92M	-$1.14	N/A

AbCellera Biologics currently has a consensus price target of $7.80, indicating a potential downside of 4.12%. Benitec Biopharma has a consensus price target of $27.00, indicating a potential upside of 116.88%. Given Benitec Biopharma's higher probable upside, analysts plainly believe Benitec Biopharma is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

61.4% of AbCellera Biologics shares are held by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by company insiders. Comparatively, 4.8% of Benitec Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, AbCellera Biologics had 4 more articles in the media than Benitec Biopharma. MarketBeat recorded 5 mentions for AbCellera Biologics and 1 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 1.87 beat AbCellera Biologics' score of 0.91 indicating that Benitec Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
AbCellera Biologics	Positive
Benitec Biopharma	Very Positive

Benitec Biopharma has a net margin of 0.00% compared to AbCellera Biologics' net margin of -181.75%. AbCellera Biologics' return on equity of -14.86% beat Benitec Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-181.75%	-14.86%	-10.62%
Benitec Biopharma	N/A	-34.82%	-34.11%

AbCellera Biologics has a beta of 1.17, suggesting that its share price is 17% more volatile than the broader market. Comparatively, Benitec Biopharma has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market.

Summary

AbCellera Biologics beats Benitec Biopharma on 10 of the 16 factors compared between the two stocks.

Get Benitec Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BNTC vs. The Competition

Export

Metric	Benitec Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$426.51M	$3.63B	$6.83B	$12.37B
Dividend Yield	N/A	2.22%	2.67%	6.11%
P/E Ratio	-10.89	21.35	25.82	24.27
Price / Sales	N/A	341.70	549.14	101.93
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	3.36	8.56	10.94	6.46
Net Income	-$37.92M	$23.92M	$3.58B	$336.87M
7 Day Performance	1.21%	3.18%	2.53%	0.45%
1 Month Performance	7.69%	0.73%	0.24%	-0.78%
1 Year Performance	9.68%	67.50%	35.55%	30.15%

Benitec Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BNTC Benitec Biopharma	1.9652 of 5 stars	$12.50 +1.1%	$27.00 +116.0%	+9.0%	$431.18M	N/A	N/A	20
GLUE Monte Rosa Therapeutics	1.6283 of 5 stars	$20.71 +10.9%	$32.50 +56.9%	+384.3%	$1.75B	$123.67M	N/A	90
ZYME Zymeworks	3.3137 of 5 stars	$23.88 +2.7%	$36.67 +53.5%	N/A	$1.74B	$81.26M	N/A	460	Trending News Gap Down
SNDX Syndax Pharmaceuticals	3.1483 of 5 stars	$19.61 +1.5%	$42.55 +117.0%	+135.7%	$1.74B	$217.17M	N/A	110	Positive News
ANAB AnaptysBio	3.789 of 5 stars	$59.43 -0.9%	$81.82 +37.7%	+181.0%	$1.73B	$232.39M	N/A	100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BNTC) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Benitec Biopharma (BNTC) Competitors

BNTC vs. GLUE, ZYME, SNDX, ANAB, and ABCL

How does Benitec Biopharma compare to Monte Rosa Therapeutics?

Summary

How does Benitec Biopharma compare to Zymeworks?

Summary

How does Benitec Biopharma compare to Syndax Pharmaceuticals?

Summary

How does Benitec Biopharma compare to AnaptysBio?

Summary

How does Benitec Biopharma compare to AbCellera Biologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTC vs. The Competition

Benitec Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Benitec Biopharma (BNTC) Competitors

BNTC vs. GLUE, ZYME, SNDX, ANAB, and ABCL

How does Benitec Biopharma compare to Monte Rosa Therapeutics?

Do institutionals & insiders hold more shares of GLUE or BNTC?

Which has stronger valuation & earnings, GLUE or BNTC?

Is GLUE or BNTC more profitable?

Does the media refer more to GLUE or BNTC?

Do analysts recommend GLUE or BNTC?

Which has more risk and volatility, GLUE or BNTC?

Summary

How does Benitec Biopharma compare to Zymeworks?

Which has more volatility & risk, ZYME or BNTC?

Does the media refer more to ZYME or BNTC?

Is ZYME or BNTC more profitable?

Which has better earnings & valuation, ZYME or BNTC?

Do analysts rate ZYME or BNTC?

Do institutionals and insiders hold more shares of ZYME or BNTC?

Summary

How does Benitec Biopharma compare to Syndax Pharmaceuticals?

Which has more risk & volatility, BNTC or SNDX?

Do insiders and institutionals believe in BNTC or SNDX?

Do analysts recommend BNTC or SNDX?

Does the media prefer BNTC or SNDX?

Is BNTC or SNDX more profitable?

Which has preferable valuation and earnings, BNTC or SNDX?

Summary

How does Benitec Biopharma compare to AnaptysBio?

Is ANAB or BNTC more profitable?

Do insiders & institutionals hold more shares of ANAB or BNTC?

Which has more risk & volatility, ANAB or BNTC?

Do analysts rate ANAB or BNTC?

Which has preferable earnings and valuation, ANAB or BNTC?

Does the media refer more to ANAB or BNTC?

Summary

How does Benitec Biopharma compare to AbCellera Biologics?

Which has higher earnings and valuation, ABCL or BNTC?

Do analysts prefer ABCL or BNTC?

Do institutionals and insiders believe in ABCL or BNTC?

Does the media refer more to ABCL or BNTC?

Is ABCL or BNTC more profitable?

Which has more volatility and risk, ABCL or BNTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTC vs. The Competition

Benitec Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools